Puracap PharmaceuticalPharmaceutical Puracap
<font color="#ffff00">PuraCap Pharmaceutical LLC Season01 Episode02 script
This was a bustling summers for China's pharmaceutical corporations and investment firms that went out to buy globally and started mega-acquisitions, as China had promised to take advantage of foreign study dates and multicentre trials as part of its policy. SANOFIB and DiCE signed a $2 billion contract to produce small molecule products against previously identified goals by Biomologics; Toshiba divested its diagnostic and biomedical image department to Canon for $6 billion.
I' m sorry - this e-mail domains is not permitted. sorry - you are not permitted to use e-mail account. Enter your work e-mail adress. If there are several receivers, seperate the e-mail adresses with a semi-colon.
PuraCap Pharmaceutical LLC is pleased to announce the second FDA inspection of its Chinese manufacturing facility.
PISCATAWAY, N.J., September 18, 2017 /PRNewswire/ -- PuraCap Pharmaceutical LLC is delighted to announce that the US Food and Drug Administration (FDA) has successfully concluded another general overhaul of its affiliate softgel capsules production site, Humanwell PuraCap Pharmaceutical (Wuhan) Co, Ltd. based in Wuhan, Hubei Province of China. Furthermore, as a consequence of this audit, an outstanding ANDA was advised for authorisation.
Inspections confirm that the site complies with current Good manufacturing practices and no 483 compliance findings have been published. The FDA inspected the product from 11 to 15 September. Commenting on the decision, Dahai Guo, Chief Executive Officer, said: "This is our second FDA inspections in two years and the continued design, engineering and education necessary to meet our objective of establishing a world-class pharmaceutical production site in China.
I' m thankful for the untiring work of the Humanwell PuraCap production and engineering team." Mr. Xiaofeng Meng, Ph.D/MBA General Manager of Humanwell PuraCap Pharmaceutical (Wuhan) Co. added: "We have always benchmarked our GMP and qualitative performances and have always obtained the highest possible results in external audit of our clients and third parties.
The second FDA unannounced visit and the upcoming ANDA pre-approval is proof of our dedication to world-class excellence. For PuraCap Pharmaceutical LLC, it is an aspiring, fully integrated pharmaceutical business with a proven track record in developing, producing and delivering affordably priced, premium-grade pharmaceuticals to its clients. PuraCap's business organization fosters a two-pronged paradigm view for achieving worldwide expansion with specialized businesses in PuraCap Pharmaceutical and PuraCap International.
At PuraCap Pharmaceutical, we continue to be innovative by leveraging our softgel know-how and the development of other orally available solids option products.